Resources from the same session
182MO - Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2+ metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1): Updated overall survival (OS) results of the randomized phase III DESTINY-breast (DB-)02 study
Presenter: Sung-Bae Kim
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
267MO - Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1 interstitial lung disease/pneumonitis (ILD)
Presenter: Hope Rugo
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
LBA3 - SOLTI-1507 IPATHER: Primary results of the phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with trastuzumab and pertuzumab (HP) in patients (pts) with PIK3CA mutant (mut) HER2+ advanced breast cancer (ABC)
Presenter: Ana Mafalda Antunes De Melo e Oliveira
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
183MO - Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): Second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial
Presenter: Hope Rugo
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
1MO - HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer
Presenter: Guillermo Villacampa Javierre
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
2MO - Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial
Presenter: Ana Mafalda Antunes De Melo e Oliveira
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 183MO, 1MO and 2MO
Presenter: Thomas Bachelot
Session: Mini Oral session 1
Resources:
Slides
Webcast
3MO - Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE
Presenter: Christine Desmedt
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
4MO - Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: A translational analysis
Presenter: Paul Cottu
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 3MO and 4MO
Presenter: Cristina Saura Manich
Session: Mini Oral session 1
Resources:
Slides
Webcast